Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptau153cxa

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 6	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS 7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 8	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS 9	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 10	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS 11	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS 12	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS 13	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS 14	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 15	DEC 18	CA/CAplus patent kind codes updated
NEWS 16	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 17	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS 18	DEC 27	CA/CAplus enhanced with more pre-1907 records
NEWS 19	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 20	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 21	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 22	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

```
* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:05:56 ON 20 JAN 2007

=> file caplus uspatfull japio epful medline biosis embase scisearch
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'CAPLUS' ENTERED AT 14:06:20 ON 20 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 14:06:20 ON 20 JAN 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 14:06:20 ON 20 JAN 2007
COPYRIGHT (C) 2007 Japanese Patent Office (JPO)- JAPIO

FILE 'EPFULL' ENTERED AT 14:06:20 ON 20 JAN 2007
COPYRIGHT (C) 2007 European Patent Office / FIZ Karlsruhe

FILE 'MEDLINE' ENTERED AT 14:06:20 ON 20 JAN 2007

FILE 'BIOSIS' ENTERED AT 14:06:20 ON 20 JAN 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 14:06:20 ON 20 JAN 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 14:06:20 ON 20 JAN 2007
Copyright (c) 2007 The Thomson Corporation

=> s (drug delivery) and (ion exchange resin#)
  1 FILES SEARCHED...
L1        3603 (DRUG DELIVERY) AND (ION EXCHANGE RESIN#)

=> s l1 and avers?
L2          27 L1 AND AVERS?

=> s l2 and (anion exhange)
L3           0 L2 AND (ANION EXHANGE)

=> s l3 and (cation exchange)
L4           0 L3 AND (CATION EXCHANGE)

=> s l2 and (resin complex)
L5           0 L2 AND (RESIN COMPLEX)

=> d l2 1-27 ibib abs

L2   ANSWER 1 OF 27  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        2004:533621  CAPLUS
DOCUMENT NUMBER:         141:76773
TITLE:                   Pharmaceutical formulation containing a resinate and
                         an aversive agent
INVENTOR(S):             Hughes, Lyn
PATENT ASSIGNEE(S):      USA
SOURCE:                  U.S. Pat. Appl. Publ., 9 pp., Cont.-in-part of U.S.
                         Ser. No. 16,336.
                         CODEN: USXXCO
DOCUMENT TYPE:           Patent
LANGUAGE:                English
```

FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004126324	A1	20040701	US 2003-679785		20031006
US 2003068276	A1	20030410	US 2001-16336		20011102
JP 2003113074	A	20030418	JP 2002-269709		20020917
PRIORITY APPLN. INFO.:			US 2001-322624P	P	20010917
			US 2001-16336	A2	20011102

AB The present invention provides a pharmaceutical that includes, in combination, a resinate and an aversive agent. The resinate includes an ion exchange resin and a drug.
The drug is a controlled substance. In variants of the invention, both the aversive agent and the controlled substance are loaded onto the ion exchange resin; the aversive agent is loaded onto the ion exchange resin, and the controlled substance is not loaded onto the ion exchange resin; the controlled substance is loaded onto the ion exchange resin, and the aversive agent is not loaded onto the ion exchange resin; or, the controlled substance is loaded onto a first ion exchange resin, and the aversive agent is loaded onto an ion exchange resin different from the first ion exchange resin.

L2 ANSWER 2 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2006:334720 USPATFULL
TITLE: Serotonergic agents for treating sexual dysfunction
INVENTOR(S): Sukoff Rizzo, Stacey J., Levittown, PA, UNITED STATES
Rosenzweig-Lipson, Sharon J., East Brunswick, NJ, UNITED STATES
Childers, Wayne E., New Hope, PA, UNITED STATES
Kelly, Michael, Thousand Oaks, CA, UNITED STATES
Schechter, Lee E., Toms River, NJ, UNITED STATES
PATENT ASSIGNEE(S): Wyeth, Madison, NJ, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006287335	A1	20061221
APPLICATION INFO.:	US 2006-396307	A1	20060330 (11)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2006-330907, filed on 11 Jan 2006, PENDING Continuation of Ser. No. US 2003-441536, filed on 20 May 2003, GRANTED, Pat. No. US 7026320 Continuation of Ser. No. US 2002-218251, filed on 14 Aug 2002, GRANTED, Pat. No. US 6586436 Continuation of Ser. No. US 2001-10575, filed on 13 Nov 2001, GRANTED, Pat. No. US 6469007

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-253301P	20001128 (60)
	US 2001-297814P	20010613 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WILMER CUTLER PICKERING HALE AND DORR LLP /, 60 STATE STREET, BOSTON, MA, 02109, US
NUMBER OF CLAIMS: 39
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 999
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and compositions are provided for treating sexual dysfunction,

e.g., sexual dysfunction associated with drug treatment, using 5-HT.sub.1A receptor antagonists.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 3 OF 27 USPATFULL on STN

ACCESSION NUMBER:	2006:334718 USPATFULL
TITLE:	Serotonergic agents for treating sexual dysfunction
INVENTOR(S):	Sukoff Rizzo, Stacey J., Levittown, PA, UNITED STATES Rosenzweig-Lipson, Sharon J., East Brunswick, NJ, UNITED STATES Childers, Wayne E., New Hope, PA, UNITED STATES Kelly, Michael, Thousand Oaks, CA, UNITED STATES Schechter, Lee E., Toms River, NJ, UNITED STATES
PATENT ASSIGNEE(S):	Wyeth, Madison, NJ, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006287333	A1	20061221
APPLICATION INFO.:	US 2006-506514	A1	20060818 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2006-396307, filed on 30 Mar 2006, PENDING Continuation-in-part of Ser. No. US 2006-330907, filed on 11 Jan 2006, PENDING Continuation of Ser. No. US 2003-441536, filed on 20 May 2003, GRANTED, Pat. No. US 7026320 Continuation of Ser. No. US 2002-218251, filed on 14 Aug 2002, GRANTED, Pat. No. US 6586436 Continuation of Ser. No. US 2001-10575, filed on 13 Nov 2001, GRANTED, Pat. No. US 6469007

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-253301P	20001128 (60)
	US 2001-297814P	20010613 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	WILMER CUTLER PICKERING HALE AND DORR LLP /, 60 STATE STREET, BOSTON, MA, 02109, US
NUMBER OF CLAIMS:	13
EXEMPLARY CLAIM:	1-38
NUMBER OF DRAWINGS:	4 Drawing Page(s)
LINE COUNT:	925

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions are provided for treating sexual dysfunction, e.g., sexual dysfunction associated with drug treatment, using 5-HT.sub.1A receptor antagonists.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 4 OF 27 USPATFULL on STN

ACCESSION NUMBER:	2006:322371 USPATFULL
TITLE:	Methods and compositions for treating flushing and drug induced weight gain
INVENTOR(S):	Sinclair, David, West Roxbury, MA, UNITED STATES Langer, Robert S., Newton, MA, UNITED STATES Westphal, Christoph H., Brookline, MA, UNITED STATES Milburn, Michael, Cary, NC, UNITED STATES
PATENT ASSIGNEE(S):	Sirtris Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006276416	A1	20061207
APPLICATION INFO.:	US 2006-336258	A1	20060120 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-645962P	20050121 (60)
	US 2005-645916P	20050120 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FISH & NEAVE IP GROUP, ROPES & GRAY LLP, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624, US
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 67 Drawing Page(s)
LINE COUNT: 8123
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Provided herein are methods and compositions for treating and/or preventing flushing and/or weight gain. Methods may comprise modulating the activity or level of a sirtuin, such as SIRT1 or Sir2. Exemplary embodiments include methods and compositions for counteracting drug-induced weight gain and/or drug-induced flushing by administering a sirtuin-activating compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 5 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2006:322348 USPATFULL
TITLE: Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
INVENTOR(S): Milburn, Michael, Cary, NC, UNITED STATES
Milne, Jill, Brookline, MA, UNITED STATES
Westphal, Christoph H., Brookline, MA, UNITED STATES
Normington, Karl D., Acton, MA, UNITED STATES
Fujii, Jennifer, Lexington, MA, UNITED STATES
Dipp, Michelle, Cambridge, MA, UNITED STATES
Elliott, Peter, Marlborough, MA, UNITED STATES
PATENT ASSIGNEE(S): Sirtris Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006276393	A1	20061207
APPLICATION INFO.:	US 2006-332056	A1	20060113 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-643921P	20050113 (60)
	US 2005-667179P	20050330 (60)
	US 2005-692785P	20050622 (60)
	US 2005-736528P	20051114 (60)
	US 2005-753606P	20051223 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FISH & NEAVE IP GROUP, ROPES & GRAY LLP, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624, US
NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 53 Drawing Page(s)
LINE COUNT: 10297
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Provided herein are methods and compositions for treating or preventing neurodegenerative disorders or blood coagulation disorders. Methods may comprise modulating the activity or level of a sirtuin, such as SIRT1 or Sir2. Exemplary methods comprise contacting a cell with a sirtuin activating compound, such as a flavone, stilbene, flavanone, isoflavone, catechin, chalcone, tannin or anthocyanidin; or an inhibitory compound, such as nicotinamide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 6 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2006:28503 USPATFULL
TITLE: Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
INVENTOR(S): Sinclair, David A., West Roxbury, MA, UNITED STATES
Tsai, Li-Huei, Cambridge, MA, UNITED STATES
Nguyen, Minh Dang, Boston, MA, UNITED STATES
Howitz, Konrad T., Allentown, PA, UNITED STATES
Zipkin, Robert E., Wynnewood, PA, UNITED STATES
Bitterman, Kevin J., Boston, MA, UNITED STATES
PATENT ASSIGNEE(S): President and Fellows of Harvard College, Cambridge, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006025337	A1	20060202
APPLICATION INFO.:	US 2005-74374	A1	20050307 (11)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2004-884022, filed on 1 Jul 2004, PENDING Continuation-in-part of Ser. No. US 2004-884879, filed on 1 Jul 2004, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-483949P	20030701 (60)
	US 2003-532158P	20031223 (60)
	US 2003-483949P	20030701 (60)
	US 2003-532158P	20031223 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BLVD, BOSTON, MA, 02110, US
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 49 Drawing Page(s)
LINE COUNT: 8646
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Provided herein are methods and compositions for modulating the activity of sirtuin deacetylase protein family members; p53 activity; apoptosis; lifespan and sensitivity to stress of cells and organisms. Exemplary methods comprise contacting a cell with an activating compound, such as a flavone, stilbene, flavanone, isoflavone, catechin, chalcone, tannin or anthocyanidin; or an inhibitory compound, such as a sphingolipid, e.g., sphingosine. Also disclosed herein are methods for treating, preventing or diagnosing a disease associated with neuronal cell death, e.g., a neurodegenerative disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 7 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2005:170873 USPATFULL
TITLE: Cinnamon formulation for reducing cholesterol and/or glucose levels
INVENTOR(S): Bozicevic, Karl, Redwood City, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005147620	A1	20050707
APPLICATION INFO.:	US 2005-30363	A1	20050105 (11)

	NUMBER	DATE

PRIORITY INFORMATION: US 2004-534600P 20040105 (60)
US 2004-540732P 20040130 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BOZICEVIC, FIELD & FRANCIS LLP, 1900 UNIVERSITY AVENUE, SUITE 200, EAST PALO ALTO, CA, 94303, US
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 1135
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A formulation comprising cinnamon and an active compound such as creatine, a statin drug, niacin, lipoic acid and/or Red Yeast Rice is disclosed. The cinnamon aids in moving the active compound into cells making the active compound more effective as compared to its administration in the absence of cinnamon. Methods of treatment including methods of reducing cholesterol levels, building muscle and treating diabetes are enhanced by the co-administration of cinnamon with another compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 8 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2005:158329 USPATFULL
TITLE: Compositions for manipulating the lifespan and stress response of cells and organisms
INVENTOR(S): Sinclair, David A., West Roxbury, MA, UNITED STATES
Howitz, Konrad T., Allentown, PA, UNITED STATES
Zipkin, Robert E., Wynnewood, PA, UNITED STATES
PATENT ASSIGNEE(S): President and Fellows of Harvard College, Cambridge, MA, UNITED STATES (U.S. corporation)
BIOMOL International L.P., Plymouth Meeting, PA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005136537	A1	20050623	
APPLICATION INFO.:	US 2004-884879	A1	20040702	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-532158P	20031223 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BLVD, BOSTON, MA, 02110, US
NUMBER OF CLAIMS: 39
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 42 Drawing Page(s)
LINE COUNT: 6631
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Provided herein are methods and compositions for modulating the activity of sirtuin deacetylase protein family members; p53 activity; apoptosis; lifespan and sensitivity to stress of cells and organisms. Exemplary methods comprise contacting a cell with an activating compound, such as a flavone, stilbene, flavanone, isoflavone, catechin, chalcone, tannin or anthocyanidin; or an inhibitory compound, such as a sphingolipid, e.g., sphingosine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 9 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2005:153995 USPATFULL
TITLE: Therapeutic and diagnostic methods dependent on CYP2A enzymes

INVENTOR(S): Sellers, Edward Moncrieff, Toronto, CANADA
Tyndale, Rachel F., Toronto, CANADA
PATENT ASSIGNEE(S): Nicogen, Inc., Quebec, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6908631	B1	20050621
APPLICATION INFO.:	US 2000-584669		20000601 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 1998-CA1093, filed on 1 Dec 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-67020P	19971201 (60)
	US 1997-67021P	19971201 (60)
	US 1998-84847P	19980508 (60)
	US 1998-107392P	19981106 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Meller, Michael
LEGAL REPRESENTATIVE: Hunton & Williams LLP
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Figure(s); 23 Drawing Page(s)
LINE COUNT: 2402
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of regulating the activity of human cytochrome P450 isozyme CYP2A6 to control nicotine metabolism or decrease the production of carcinogens from procarcinogens, such as those present in tobacco smoke, in an individual by selectively inhibiting CYP2A6. Various prophylactic (i.e., prevention and treatment) compositions and methods are also described, including an improved oral nicotine composition and method comprising the use of nicotine together with an inhibitor of the CYP2A6 enzyme. Furthermore, it has been discovered that the presence in an individual of a mutant allele of human cytochrome P450 enzyme CYP2A6 (referred to throughout this specification as "CYP2A6" for brevity) is predictive of an individual who: (1) has a decreased risk of becoming a smoker, (ii) will smoke less if he/she becomes dependent, and/or (iii) may be at relatively lower risk for cancer due to both decreased smoke exposure and decreased CYP2A6 -mediated activation of tobacco smoke and other procarcinogenic substrates. This invention provides diagnostic methods for predicting tobacco dependence risk and risk for cancers related to CYP2A6 substrates in an individual by analyzing for the presence of a mutant genotype for human cytochrome P450 enzyme CYP2A6 in an individual, ranging from gene duplication (multiple copies of CYP2A6) to single or even no copies due to null alleles or gene deletion.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 10 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2005:137641 USPATFULL
TITLE: Compositions and methods for treatment of nervous system disorders
INVENTOR(S): Suffin, Stephen C., Sherman Oaks, CA, UNITED STATES
Emory, W. Hamlin, Malibu, CA, UNITED STATES
Brandt, Leonard, San Juan Capistrano, CA, UNITED STATES
PATENT ASSIGNEE(S): CNS Response (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005118286	A1	20050602
APPLICATION INFO.:	US 2004-972188	A1	20041022 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2003-697497, filed on 30 Oct 2003, PENDING

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MEDLEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA, 94105, US
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 5033
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention contemplates compositions and methods to treat patients having a nervous system disorder with a formulation comprising an anticonvulsant and a neuroactive modulator. Also described is a method to predict the probability of a significant recovery when a treating an individual patient having a nervous system disorder with a formulation comprising an anticonvulsant and a neuroactive modulator. Specifically, methods for predicting patient prognosis include, but are not limited to, quantitative electroencephalography, psychometric test batteries, biological indicators, brain metabolic indicators, genotype profiles, neuroimaging, objective test measurements and multi-modalities. The present invention also discloses a device providing an organized dispensation of the above formulations such that the patient or medical personnel may easily and accurately decrease the daily dosage of a third drug and increase the daily dosage of a formulation comprising an anticonvulsant and a neuroactive modulator.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 11 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2005:124960 USPATFULL
TITLE: Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
INVENTOR(S): Olson, Lisa Maria, Creve Coeur, MO, UNITED STATES
PATENT ASSIGNEE(S): Pharmacia Corporation, Chesterfield, MO, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005107350	A1	20050519	
APPLICATION INFO.:	US 2004-917104	A1	20040812	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2003-497416P	20030822	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: James E. Davis, Harness, Dickey & Pierce, P. L. C., 7700 Bonhomme, Suite 400, Clayton, MO, 63105, US
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
LINE COUNT: 3405
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes a novel method for preventing or treating bone disorders and bone disorder-related complications in a subject involving a monotherapy with a Cox-2 inhibitor or a combination therapy with a Cox-2 inhibitor and a bone disorder treatment agent. Also described are therapeutic compositions comprising a Cox-2 inhibitor and a bone disorder treatment agent. Pharmaceutical compositions and kits for implementing the present method are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 12 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2005:112226 USPATFULL
TITLE: Compositions and methods for treatment of nervous system disorders
INVENTOR(S): Suffin, Stephen C., Sherman Oaks, CA, UNITED STATES
Emory, W. Hamlin, Malibu, CA, UNITED STATES
Brandt, Leonard, San Juan Capistrano, CA, UNITED STATES
PATENT ASSIGNEE(S): CNS Response, Santa Anna, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005096311	A1	20050505	
APPLICATION INFO.:	US 2003-697497	A1	20031030	(10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Peter G. Carroll, MEDLEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA, 94105, US
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 5022
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention contemplates compositions and methods to treat patients having a nervous system disorder with a formulation comprising an anticonvulsant and a neuroactive modulator. Also described is a method to predict the probability of a significant recovery when a treating an individual patient having a nervous system disorder with a formulation comprising an anticonvulsant and a neuroactive modulator. Specifically, methods for predicting patient prognosis include, but are not limited to, quantitative electroencephalography, psychometric test batteries, biological indicators, brain metabolic indicators, genotype profiles, neuroimaging, objective test measurements and multi-modalities. The present invention also discloses a device providing an organized dispensation of the above formulations such that the patient or medical personnel may easily and accurately decrease the daily dosage of a third drug and increase the daily dosage of a formulation comprising an anticonvulsant and a neuroactive modulator.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 13 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2005:112172 USPATFULL
TITLE: Compositions for manipulating the lifespan and stress response of cells and organisms
INVENTOR(S): Sinclair, David A., West Roxbury, MA, UNITED STATES
PATENT ASSIGNEE(S): President and Fellows of Harvard College, Cambridge, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005096256	A1	20050505	
APPLICATION INFO.:	US 2004-884022	A1	20040701	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2003-483949P	20030701	(60)
	US 2003-532158P	20031223	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BLVD, BOSTON, MA, 02110, US
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 42 Drawing Page(s)

LINE COUNT: 6583
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Provided herein are methods and compositions for modulating the activity of sirtuin deacetylase protein family members; p53 activity; apoptosis; lifespan and sensitivity to stress of cells and organisms. Exemplary methods comprise contacting a cell with an activating compound, such as a flavone, stilbene, flavanone, isoflavone, catechin, chalcone, tannin or anthocyanidin; or an inhibitory compound, such as a sphingolipid, e.g., sphingosine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 14 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2005:24092 USPATFULL
TITLE: Therapeutic and diagnostic methods dependent on CYP2A enzymes
INVENTOR(S): Sellers, Edward Moncrieff, Toronto, CANADA
Tyndale, Rachel F., Toronto, CANADA
PATENT ASSIGNEE(S): Nicogen, Inc., St. Lurent, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005020641	A1	20050127
APPLICATION INFO.:	US 2004-815995	A1	20040402 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-584669, filed on 1 Jun 2000, PENDING Continuation of Ser. No. WO 1998-CA10193, filed on 1 Dec 1998, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-67020P	19971201 (60)
	US 1997-67021P	19971201 (60)
	US 1998-84847P	19980508 (60)
	US 1998-107392P	19981106 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUNTON & WILLIAMS LLP, INTELLECTUAL PROPERTY DEPARTMENT, 1900 K STREET, N.W., SUITE 1200, WASHINGTON, DC, 20006-1109
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 2539
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of regulating the activity of human cytochrome P450 isozyme CYP2A6 to control nicotine metabolism or decrease the production of carcinogens from procarcinogens, such as those present in tobacco smoke, in an individual by selectively inhibiting CYP2A6. Various prophylactic (i.e., prevention and treatment) compositions and methods are also described, including an improved oral nicotine composition and method comprising the use of nicotine together with an inhibitor of the CYP2A6 enzyme. Furthermore, it has been discovered that the presence in an individual of a mutant allele of human cytochrome P450 enzyme CYP2A6 (referred to throughout this specification as "CYP2A6" for brevity) is predictive of an individual who: (1) has a decreased risk of becoming a smoker, (ii) will smoke less if he/she becomes dependent, and/or (iii) may be at relatively lower risk for cancer due to both decreased smoke exposure and decreased CYP2A6-mediated activation of tobacco smoke and other procarcinogenic substrates. This invention provides diagnostic methods for predicting tobacco dependence risk and risk for cancers related to CYP2A6 substrates in an individual by analyzing for the presence of a mutant genotype for human cytochrome P450 enzyme CYP2A6 in an individual, ranging from gene duplication (multiple copies of CYP2A6)

to single or even no copies due to null alleles or gene deletion.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 15 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2005:4324 USPATFULL
TITLE: Dendritic enriched secreted lymphocyte activation molecule
INVENTOR(S): Ruben, Steven M., Brookeville, MD, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005003427	A1	20050106
APPLICATION INFO.:	US 2004-892171	A1	20040716 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2002-62523, filed on 5 Feb 2002, PENDING Continuation-in-part of Ser. No. WO 2000-US21130, filed on 3 Aug 2000, PENDING Continuation-in-part of Ser. No. US 1999-369248, filed on 5 Aug 1999, GRANTED, Pat. No. US 6620912 Continuation-in-part of Ser. No. US 1999-244110, filed on 4 Feb 1999, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-267523P	20010206 (60)
	US 2000-190062P	20000317 (60)
	US 1998-73962P	19980206 (60)
	US 1998-78572P	19980319 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY GROVE ROAD, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 12514
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a novel human protein called Dendritic Enriched Secreted Lymphocyte Activation Molecule, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 16 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2004:260604 USPATFULL
TITLE: Brain-associated inhibitor of tissue-type plasminogen activator
INVENTOR(S): Hastings, Gregg A., Westlake Village, CA, UNITED STATES
Coleman, Timothy A., Derwood, MD, UNITED STATES
Dillon, Patrick J., Carlsbad, CA, UNITED STATES
Lawrence, Daniel A., Derwood, MD, UNITED STATES
Sandkvist, Maria, Derwood, MD, UNITED STATES
Yepes, Manuel, Rockville, MD, UNITED STATES
Wong, Michael K. K., East Amhurst, NY, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)
The American Red Cross, Rockville, MD (U.S.

corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004203101	A1	20041014
APPLICATION INFO.:	US 2004-752041	A1	20040107 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-987021, filed on 13 Nov 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-957485, filed on 21 Sep 2001, ABANDONED Continuation of Ser. No. US 2000-521664, filed on 8 Mar 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-722292, filed on 28 Nov 2000, GRANTED, Pat. No. US 6541452 Division of Ser. No. US 1999-348817, filed on 8 Jul 1999, GRANTED, Pat. No. US 6191260 Division of Ser. No. US 1997-948997, filed on 10 Oct 1997, GRANTED, Pat. No. US 6008020 Continuation-in-part of Ser. No. US 2003-355208, filed on 31 Jan 2003, PENDING Division of Ser. No. US 2001-957485, filed on 21 Sep 2001, ABANDONED Continuation of Ser. No. US 2000-521664, filed on 8 Mar 2000, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-247971P	20001114 (60)
	US 1999-123704P	19990310 (60)
	US 1996-28117P	19961011 (60)
	US 1999-123704P	19990310 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY GROVE ROAD, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Page(s)
LINE COUNT: 10699
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel BAIT protein which is a member of serpin superfamily which is expressed primarily in brain tissue. In particular, isolated nucleic acid molecules are provided encoding the human and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of BAIT activity. Also provided are diagnostic methods for detecting nervous system-related disorders and therapeutic methods for treating nervous system-related disorders. Additionally, the present invention is related to methods of treating patients with BAIT polynucleotides or polypeptides, wherein said patients have had seizures or epilepsy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 17 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2004:51449 USPATFULL
TITLE: Brain associated inhibitor of tissue - type plasminogen activator
INVENTOR(S): Lawrence, Daniel A., Derwood, MD, UNITED STATES
Yepes, Manuel, Alexandria, VA, UNITED STATES
Sandkvist, Maria, Derwood, MD, UNITED STATES
Coleman, Timothy A., Gaithersburg, MD, UNITED STATES
Wong, Michael K.K., Wexford, PA, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)
The American Red Cross, Falls Church, VA, UNITED STATES, 22042 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004038880	A1	20040226
	US 7087574	B2	20060808
APPLICATION INFO.:	US 2003-355208	A1	20030131 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2001-957485, filed on 21 Sep 2001; ABANDONED Continuation of Ser. No. US 2000-521664, filed on 8 Mar 2000, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-123704P	19990310 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 24 Drawing Page(s)
LINE COUNT: 9150
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel BAIT protein which is a member of serpin superfamily which is expressed primarily in brain tissue. In particular, isolated nucleic acid molecules are provided encoding the human and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of BAIT activity. Also provided are diagnostic methods for detecting nervous system-related disorders and therapeutic methods for treating nervous system-related disorders. Additionally, the present invention is related to methods of treating patients with BAIT polynucleotides or polypeptides, wherein said patients have had a stroke.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 18 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2003:44724 USPATFULL
TITLE: Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
INVENTOR(S): Tang, Y. Tom, San Jose, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003032034	A1	20030213
APPLICATION INFO.:	US 2002-125852	A1	20020419 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-799451, filed on 5 Mar 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-316368P	20010830 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Luisa Bigornia, HYSEQ, INC., 670 Almanor Avenue, Sunnyvale, CA, 94085
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 5060
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted stem cell growth factor-like polypeptides. In particular, the invention relates to novel stem cell growth factor-like

polypeptides, including novel proteins named SCGF3248Fk081_aa2, SCGF3248Fk081_aa1, SCGFFk081_aa3, and SCGF323401Fe131_aa1. Other aspects of the invention include vectors containing processes for producing novel human secreted stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 19 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2003:30380 USPATFULL
TITLE: Dendritic enriched secreted lymphocyte activation molecule
INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003022327	A1	20030130
	US 7012134	B2	20060314
APPLICATION INFO.:	US 2002-62523	A1	20020205 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2000-US21130, filed on 3 Aug 2000, UNKNOWN Continuation-in-part of Ser. No. US 1999-369248, filed on 5 Aug 1999, PENDING Continuation-in-part of Ser. No. WO 1999-US2415, filed on 4 Feb 1999, UNKNOWN Continuation-in-part of Ser. No. US 1999-244110, filed on 4 Feb 1999, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-267523P	20010206 (60)
	US 2000-190062P	20000317 (60)
	US 1998-73962P	19980206 (60)
	US 1998-78572P	19980319 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 12477
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a novel human protein called Dendritic Enriched Secreted Lymphocyte Activation Molecule, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 20 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2002:295102 USPATFULL
TITLE: Brain-associated inhibitor of tissue-type plasminogen activator
INVENTOR(S): Yepes, Manuel, Alexandria, VA, UNITED STATES
Lawrence, Daniel A., Derwood, MD, UNITED STATES
Coleman, Timothy A., Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002165147	A1	20021107
APPLICATION INFO.:	US 2001-987021	A1	20011113 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-957485, filed on 21 Sep 2001, PENDING Continuation of Ser. No. US 2000-521664, filed on 8 Mar 2000, ABANDONED Continuation of Ser. No. US 2000-722292, filed on 28 Nov 2000, PENDING Division of Ser. No. US 1999-348817, filed on 8 Jul 1999, GRANTED, Pat. No. US 6191260 Division of Ser. No. US 1997-948997, filed on 10 Oct 1997, GRANTED, Pat. No. US 6008020

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-247971P	20001114 (60)
	US 1999-123704P	19990310 (60)
	US 1996-28117P	19961011 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Page(s)
LINE COUNT: 9975
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel BAIT protein which is a member of serpin superfamily which is expressed primarily in brain tissue. In particular, isolated nucleic acid molecules are provided encoding the human and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of BAIT activity. Also provided are diagnostic methods for detecting nervous system-related disorders and therapeutic methods for treating nervous system-related disorders. Additionally, the present invention is related to methods of treating patients with BAIT polynucleotides or polypeptides, wherein said patients have had seizures or epilepsy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 21 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2002:259589 USPATFULL
TITLE: Brain-associated inhibitor of tissue-type plasminogen activator
INVENTOR(S): Lawrence, Daniel A., Derwood, MD, UNITED STATES
Yepes, Manuel, Alexandria, VA, UNITED STATES
Sandkvist, Maria, Derwood, MD, UNITED STATES
Wong, Michael K. K., Wexford, PA, UNITED STATES
Coleman, Timothy A., Gaithersburg, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002143165	A1	20021003
APPLICATION INFO.:	US 2001-957485	A1	20010921 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-521664, filed on 8 Mar 2000, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-123704P	19990310 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Page(s)
LINE COUNT: 9239
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a novel BAIT protein which is a member of serpin superfamily which is expressed primarily in brain tissue. In particular, isolated nucleic acid molecules are provided encoding the human and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of BAIT activity. Also provided are diagnostic methods for detecting nervous system-related disorders and therapeutic methods for treating nervous system-related disorders. Additionally, the present invention is related to methods of treating patients with BAIT polynucleotides or polypeptides, wherein said patients have had a stroke.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 22 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2000:1844 USPATFULL
TITLE: Method of protein therapy by orally administering crosslinked protein crystals
INVENTOR(S): Navia, Manuel A., Lexington, MA, United States
St. Clair, Nancy L., Charlestown, MA, United States
PATENT ASSIGNEE(S): Vertex Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6011001		20000104
APPLICATION INFO.:	US 1995-484978		19950607 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-17510, filed on 12 Feb 1993, now patented, Pat. No. US 5618710 which is a continuation-in-part of Ser. No. US 1992-864424, filed on 6 Apr 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-720237, filed on 24 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-562280, filed on 3 Aug 1990, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Naff, David M.
LEGAL REPRESENTATIVE: Fish & Neave, Haley, Jr., James F., Pierri, Margaret A.
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 3038
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A protein such as an enzyme or antibody is immobilized by crosslinking crystals of the protein with a multifunctional crosslinking agent. The crosslinked protein crystals may be lyophilized for storage. A preferred protein is an enzyme such as thermolysin, elastase, asparaginase, lysozyme, lipase or urease. Crosslinked enzyme crystals preferably retain at least 91% activity after incubation for three hours in the presence of a concentration of Pronase.TM. that causes the soluble uncrosslinked form of the enzyme to lose at least 94% of its initial activity under the same conditions. A preferred enzyme:Pronase.TM. ratio is 40:1. Enzyme crystals that are crosslinked may be microcrystals having a cross-section of 10.sup.-1 mm or less. Crosslinked enzyme or antibody crystals may be used in an assay, diagnostic kit or biosensor for detecting an analyte, in an extracorporeal device for altering a component of a fluid, in producing a product such as using crosslinked thermolysin crystals to produce aspartame and in separating a substance from a mixture. Enzyme or non-enzyme protein therapy can be performed by

administering orally crosslinked enzyme crystals or crosslinked non-enzyme protein crystals that have a therapeutic affect. The crosslinked crystals have improved stability to proteases in the gut. Crosslinked lipase crystals may be administered for treatment where there is pancreatic insufficiency and/or fat malabsorption conditions in which lipase secretion is abnormally low.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 23 OF 27 USPATFULL on STN
ACCESSION NUMBER: 1999:166809 USPATFULL
TITLE: Biosensors, extracorporeal devices and methods for detecting substances using crosslinked protein crystals
INVENTOR(S): Navia, Manuel A., Lexington, MA, United States
St. Clair, Nancy L., Charlestown, MA, United States
PATENT ASSIGNEE(S): Vertex Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6004768		19991221
APPLICATION INFO.:	US 1995-484238		19950607 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-17510, filed on 12 Feb 1993, now patented, Pat. No. US 5618710 which is a continuation-in-part of Ser. No. US 1992-864424, filed on 6 Apr 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-720237, filed on 24 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-562280, filed on 3 Aug 1990, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Naff, David M.
LEGAL REPRESENTATIVE: Fish & Neave, Haley, Jr., James F., Pierri, Margaret A.
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 3066
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Proteins such as enzymes and antibodies are immobilized by crosslinking crystals of the proteins such as microcrystals having a cross-section of 10.sup.-1 mm or less with a multifunctional crosslinking agent. The crosslinked protein crystals may be lyophilized for storage. Crystals of an enzyme such as thermolysin, elastase, asparaginase, lysozyme, lipase or urease may be crosslinked to provide crosslinked enzyme crystals that retain at least 91% activity after incubation for three hours in the presence of a concentration of Pronase.TM. that causes the soluble uncrosslinked form of the enzyme to lose at least 94% of its initial activity under the same conditions. A preferred Pronase.TM.:enzyme ratio is 1:40. Crosslinked enzyme or antibody crystals may be used in an assay, diagnostic kit or biosensor for detecting an analyte, in an extracorporeal device for altering a component of a fluid, in producing a product such as using crosslinked thermolysin crystals to produce aspartame, in separating a substance from a mixture, and in therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 24 OF 27 USPATFULL on STN
ACCESSION NUMBER: 1999:136679 USPATFULL
TITLE: Methods of enzyme therapy by orally administering crosslinked enzyme crystals
INVENTOR(S): Navia, Manuel A., Lexington, MA, United States
St. Clair, Nancy L., Charlestown, MA, United States
PATENT ASSIGNEE(S): Vertex Pharmaceuticals, Inc., Cambridge, MA, United

States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5976529		19991102
APPLICATION INFO.:	US 1995-477109		19950607 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-17510, filed on 12 Feb 1993, now patented, Pat. No. US 5618710 which is a continuation-in-part of Ser. No. US 1992-864424, filed on 6 Apr 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-720237, filed on 24 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-562280, filed on 3 Aug 1990, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Naff, David M.
LEGAL REPRESENTATIVE: Fish & Neave, Haley, Jr., James F., Pierri, Margaret A.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 2922
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A protein such as an enzyme or antibody is immobilized by crosslinking crystals of the protein with a multifunctional crosslinking agent. The crosslinked protein crystals may be lyophilized for storage. A preferred protein is an enzyme such as thermolysin, elastase, asparaginase, lysozyme, lipase or urease. Crosslinked enzyme crystals preferably retain at least 91% activity after incubation for three hours in the presence of a concentration of Pronase.TM. that causes the soluble uncrosslinked form of the enzyme to lose at least 94% of its initial activity under the same conditions. A preferred enzyme:Pronase.TM. ratio is 1:40. Enzyme crystals that are crosslinked may be microcrystals having a cross-section of 10.sup.-1 mm or less. Crosslinked enzyme or antibody crystals may be used in an assay, diagnostic kit or biosensor for detecting an analyte, in an extracorporeal device for altering a component of a fluid, in producing a product such as using crosslinked thermolysin crystals to produce aspartame and in separating a substance from a mixture. Enzyme therapy such as lipase therapy can be performed by administering orally crosslinked lipase crystals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 25 OF 27 USPATFULL on STN
ACCESSION NUMBER: 1998:156918 USPATFULL
TITLE: Crosslinked protein crystals
INVENTOR(S): Navia, Manuel A., Lexington, MA, United States
St. Clair, Nancy L., Charlestown, MA, United States
PATENT ASSIGNEE(S): Vertex Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5849296		19981215
APPLICATION INFO.:	US 1995-476267		19950607 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-17510, filed on 12 Feb 1993, now patented, Pat. No. US 5618710 which is a continuation-in-part of Ser. No. US 1992-864424, filed on 6 Apr 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-720237, filed on 24 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-562280, filed on 3 Aug 1990, now abandoned

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: Naff, David M.
LEGAL REPRESENTATIVE: Fish & Neave, Haley, Jr., James F., Pierri, Margaret A.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 3122
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A protein such as an enzyme or antibody is immobilized by crosslinking crystals of the protein with a multifunctional crosslinking agent. The crosslinked protein crystals may be lyophilized for storage. A preferred protein is an enzyme such as thermolysin, elastase, asparaginase, lysozyme, lipase or urease. Crosslinked enzyme crystals preferably retain at least 91% activity after incubation for three hours in the presence of a concentration of Pronase.TM. that causes the soluble uncrosslinked form of the enzyme to lose at least 94% of its initial activity under the same conditions. A preferred enzyme:Pronase.TM. ratio is 1:40. Enzyme crystals that are crosslinked may be microcrystals having a cross-section of 10.sup.-1 mm or less. Crosslinked enzyme or antibody crystals may be used in an assay, diagnostic kit or biosensor for detecting an analyte, in an extracorporeal device for altering a component of a fluid, in producing a product such as using crosslinked thermolysin crystals to produce aspartame, in separating a substance from a mixture, and in therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 26 OF 27 USPATFULL on STN
ACCESSION NUMBER: 97:29369 USPATFULL
TITLE: Crosslinked enzyme crystals
INVENTOR(S): Navia, Manuel A., Lexington, MA, United States
St. Clair, Nancy L., Charlestown, MA, United States
PATENT ASSIGNEE(S): Vertex Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5618710		19970408
APPLICATION INFO.:	US 1993-17510		19930212 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-864424, filed on 6 Apr 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-720237, filed on 24 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-562280, filed on 3 Aug 1990, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Naff, David M.
LEGAL REPRESENTATIVE: Fish & Neave, Haley, Jr., James F., Pierri, Margaret A.
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 3106
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A protein such as an enzyme of antibody is immobilized by crosslinking crystals of the protein with a multifunctional crosslinking agent. The crosslinked protein crystals may be lyophilized for storage. A preferred protein is an enzyme such as thermolysin, elastase, asparaginase, lysozyme, lipase or urease. Crosslinked enzyme crystals preferably retain at least 91% activity after incubation for three hours in the presence of a concentration of Pronase.TM. that causes the soluble uncrosslinked form of the enzyme to lose at least 94% of its initial activity under the same conditions. A preferred enzyme:Pronase.TM. ratio is 1:40. Enzyme crystals that are crosslinked may be microcrystals

having a cross-section of 10.sup.-1 mm or less. Crosslinked enzyme or antibody crystals may be used in an assay, diagnostic kit or biosensor for detecting an analyte, in an extracorporeal device for altering a component of a fluid, in producing a product such as using crosslinked thermolysin crystals to produce aspartame, in separating a substance from a mixture, and in therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 27 OF 27 EPFULL COPYRIGHT 2007 EPO/FIZ KA on STN

ACCESSION NUMBER: 1998:91133 EPFULL
ENTRY DATE PUBLICATION: 20060810
UPDATE DATE PUBLICAT.: 20060810
DATA UPDATE DATE: 20060809
DATA UPDATE WEEK: 200632
TITLE (ENGLISH): COMBINATION OF CYP2A ENZYME INHIBITORS AND NICOTINE AND THEIR THERAPEUTIC USE
TITLE (FRENCH): COMBINAISONS D'INHIBITEURS DES ENZYMES CYP2A ET DE NICOTINE ET LEUR UTILISATION THERAPEUTIQUE
TITLE (GERMAN): WIRKSTOFFKOMBINATION AUS CYP2A ENZYME INHIBITOREN UND NIKOTINE UND IHRE THERAPEUTISCHE ANWENDUNG
INVENTOR(S): SELLERS, Edward, M., 78 Baby Point Crescent, Toronto, Ontario M6S 1B2, CA; TYNDALE, Rachel, F., 28 Brunswick Avenue 5, Toronto, Ontario M5S 2L7, CA
PATENT APPLICANT(S): Nicogen Inc., 720 King Street West Suit 700, Toronto ON M5V 2T3, CA
PATENT APPL. NUMBER: 7125570
AGENT: Cornish, Kristina Victoria Joy, et al, Kilburn & Strode, 20 Red Lion Street, London WC1R 4PJ, GB
AGENT NUMBER: 79701
DOCUMENT TYPE: Patent
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
LANGUAGE OF PROCEDURE: English
LANGUAGE OF TITLE: German; English; French
PATENT INFO TYPE: EPB1 Granted patent
PATENT INFORMATION:
PATENT INFORMATION:

NUMBER	KIND	DATE
NUMBER	KIND	DATE
EP 1033979	B1	20060809
WO 9927919		19990610

DESIGNATED STATES: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

APPLICATION INFO.:	EP 1998-956735	A	19981201
	WO 1998-CA1093	A	19981201
PRIORITY INFO.:	US 1997-67020P	P	19971201
	US 1997-67021P	P	19971201
	US 1998-84847P	P	19980508
	US 1998-107392P	P	19981106

CITED NON PATENT LIT.: M. NAKAJIMA ET AL.: "Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes." J. PHARMACOL. EXP. THERAP., vol. 277, no. 2, 1996, pages 1010-1015, XP002050001;

M. NAKAJIMA ET AL.: "Role of human cytochrome P4502A6 in C-oxidation of nicotine." DRUG METABOL. DISPOS., vol. 24, no. 11, 1996, pages 1212-1217, XP002050002;

A. TSUJIMOTO ET AL.: "Potent inhibitory action of pilocarpine on hepatic drug metabolism." JPN. J. PHARMACOL., vol. 22, no. 5, 1972, pages 736-739,

XP002050003;

A. TSUJIMOTO ET AL.: "A study of the nature of pilocarpine inhibition of hepatic drug-metabolizing enzymes." BIOCHEM. PHARMACOL., vol. 26, no. 21, 1977, pages 2072-2074, XP002050004;

H. FOTH ET AL.: "Nicotine metabolism in isolated perfused lung and liver of phenobarbital- and benzoflavone-treated rats." ARCH. TOXICOL., vol. 65, no. 1, 1991, pages 68-72, XP002050005;

G.A. KYEREMATEN ET AL.: "Metabolism of nicotine by hepatocytes." BIOCHEM. PHARMACOL., vol. 40, no. 8, 1990, pages 1747-1756, XP002050006;

H. YAMAZAKI ET AL.: "Cytochrome P450 sE1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes." CARCINOGENESIS, vol. 13, no. 10, 1992, pages 1789-1794, XP002050007

CITED PATENT LIT.: WO 9534679 A